NeOnc’s Brain Cancer Drug Forges Global Path Through UAE Approval

CALABASAS, CA – June 16, 2026 – In the relentless battle against one of oncology's most formidable enemies, glioblastoma, small-cap biotech NeOnc Technologies (Nasdaq: NTHI) has just opened a critical new front. The company announced it has secured Investigational New Drug (IND) approval from the Department of Health – Abu Dhabi (DOH) for NEO212, its novel oral therapy for aggressive brain tumors. This clearance not only allows NeOnc to initiate Phase 2 trials in the United Arab Emirates but also signals a masterful strategic pivot in the global drug development race.

Following a successful Phase 1 trial in the U.S. that established a recommended dose of 610 mg, this first international green light for NEO212 is far more than a procedural milestone. It represents a validation of NeOnc’s science and a calculated move to build parallel clinical and regulatory pathways. By engaging with both the U.S. FDA and international bodies like the DOH, the company is constructing a multi-pronged strategy designed to accelerate development, diversify risk, and tap into burgeoning global innovation hubs.

For patients with glioblastoma, a cancer with a grim median survival of just 12 to 18 months, any acceleration in bringing new therapies to market is a profound source of hope. For investors and industry observers, NeOnc’s move offers a compelling case study in how modern biopharmaceutical strategy is evolving beyond traditional, single-market approaches.

A Trojan Horse for a Deadly Foe

To understand the significance of NEO212, one must first appreciate the fortress it's designed to breach: the human brain. Glioblastoma is notoriously difficult to treat not only because of its aggressive nature but also due to the blood-brain barrier (BBB), a highly selective membrane that protects the brain from toxins but also blocks most chemotherapy drugs from reaching their target. The current standard of care, temozolomide (TMZ), has been a cornerstone for two decades, but its effectiveness is often limited by poor BBB penetration and the tumor's ability to develop resistance, particularly through the DNA repair protein MGMT.

NEO212 is engineered to be a molecular Trojan horse. It's a conjugate molecule that chemically links temozolomide to perillyl alcohol (POH), a naturally occurring compound found in citrus oils. POH is a small, lipophilic molecule with an innate ability to cross the blood-brain barrier. By hitching a ride on POH, the TMZ payload is designed to be ferried directly to the tumor site in higher concentrations than is possible with conventional oral TMZ. Preclinical data suggests this approach is not only more effective at penetrating the brain but may also overcome TMZ resistance, a game-changer for a large subset of patients.

“This clearance represents an important international milestone for NeOnc and for the NEO212 program,” said Amir Heshmatpour, Chief Executive Officer, Executive Chairman and President of NeOnc. “Brain cancers such as glioblastoma remain among the most difficult diseases in oncology, and patients urgently need new treatment options.”

The Phase 1 study provided encouraging initial evidence, with reports of “potential durable disease stabilization” in heavily pretreated patients—individuals who had already exhausted other options. The move to Phase 2 will more rigorously test whether this innovative delivery system can translate into meaningful clinical outcomes and extend survival in a patient population that desperately needs a breakthrough.

A Global Gambit to Accelerate Development

While the science is compelling, NeOnc's business strategy is equally noteworthy. Pursuing simultaneous regulatory pathways in the U.S. and the UAE is a sophisticated gambit. It allows the company to gather clinical data from a more diverse patient population and provides operational flexibility. Should one regulatory process encounter delays, the other can continue to advance, de-risking the overall development timeline.

This international strategy is underpinned by robust financial and strategic partnerships. The company recently secured a $50 million strategic partnership with Quazar Investment, centered on its Abu Dhabi-based subsidiary, NuroCure. This infusion of capital is earmarked to accelerate the clinical programs for both NEO212 and its sister compound, NEO100 (a purified form of perillyl alcohol), across the Middle East and North Africa (MENA) region. This isn't just about funding; it's about building an integrated operational hub in a key emerging market.

Investor confidence appears to be solidifying around this strategy. Despite a challenging market that has seen NTHI’s stock decline over the past six months, analyst price targets remain bullish, ranging from $13 to $20. More tellingly, CEO Amir Heshmatpour has demonstrated significant personal conviction, purchasing nearly $1 million of company stock on the open market over the past year. Such strong insider buying is often interpreted as a signal of management’s deep-seated belief in the company’s trajectory.

Abu Dhabi's Rise as a Clinical Trial Powerhouse

NeOnc's choice of the UAE is no accident. The Department of Health – Abu Dhabi has been actively cultivating an environment conducive to cutting-edge clinical research. By offering a clear and collaborative regulatory framework and investing in world-class healthcare infrastructure, such as Cleveland Clinic Abu Dhabi, the emirate is positioning itself as a premier destination for life sciences innovation. For companies like NeOnc, this provides access to a sophisticated clinical trial ecosystem and an opportunity to be at the forefront of a burgeoning biotech hub.

The DOH approval is just the beginning. NeOnc has also submitted applications for its NEO100 clinical programs in the UAE, signaling a long-term commitment to the region. If approved, this would further cement the UAE’s role in the development of a new generation of CNS therapies and solidify NeOnc’s foothold in a market eager to embrace medical innovation. This symbiotic relationship—where innovative companies gain an efficient pathway and host nations build their knowledge economy—is a hallmark of the next industrial revolution in healthcare.

As NeOnc prepares to enroll its first patients in the UAE, subject to local IRB approval, the company is navigating a complex but promising path. Its lead candidates are protected by a formidable patent portfolio of 176 patents and applications extending to 2038, securing its intellectual high ground in a competitive field. While other companies are exploring different modalities like immunotherapy and oncolytic viruses, NeOnc’s strategy of optimizing a proven chemotherapy agent through a novel delivery system offers a distinct and potentially faster path to improving the standard of care. The journey for NEO212 is far from over, but with its dual-track global strategy now firmly in motion, NeOnc has demonstrated a clear vision for how to build a 21st-century biopharmaceutical enterprise.